Trial Profile
Phase IV, multicenter, randomized, single-blind, study to evaluate the immunogenicity, reactogenicity amp; safety of the live attenuated rotavirus vaccine ROTAVAC as a 3 dose series when administered simultaneously with or without the buffering agent following in healthy infants - ROTAVAC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs ORV 116E (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
- 14 Dec 2018 Status changed from recruiting to completed.
- 06 May 2014 New trial record